GATM and glioblastoma: This phenomenon has been demonstrated in mice bearing human glioblastoma xenografts, in that progressively decreasing AGAT activity in a tumour cell line with AGAT activity of 45 fmol mg−1 protein by administering O6BG does not result in any further enhancement of alkylator antitumour efficacy (Kokkinakis et al, 2001).